About the Authors
- Federico C. F. Calboli
-
* E-mail: f.calboli@imperial.ac.uk
Affiliation Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom
- Federica Tozzi
-
Affiliation Genetics Division, Drug Discovery, GlaxoSmithKline R&D, Verona, Italy
- Nicholas W. Galwey
-
Affiliation Discovery Biometrics Respiratory, GlaxoSmithKline, Greenford, United Kingdom
- Athos Antoniades
-
Affiliation Department of Computer Science, University of Cyprus, Nicosia, Cyprus
- Vincent Mooser
-
Affiliation Genetics Division, Drug Discovery, GlaxoSmithKline R&D, Upper Merion, Pennsylvania, United States of America
- Martin Preisig
-
Affiliation Department of Psychiatry, University Hospital Center and University of Lausanne, Lausanne, Switzerland
- Peter Vollenweider
-
Affiliation Department of Internal Medicine, University Hospital Center and University of Lausanne, Lausanne, Switzerland
- Dawn Waterworth
-
Affiliation Genetics Division, Drug Discovery, GlaxoSmithKline R&D, Upper Merion, Pennsylvania, United States of America
- Gerard Waeber
-
Affiliation Department of Internal Medicine, University Hospital Center and University of Lausanne, Lausanne, Switzerland
- Michael R. Johnson
-
Contributed equally to this work with: Michael R. Johnson, Pierandrea Muglia, David J. Balding
Affiliation Department of Clinical Neurosciences, Imperial College London, London, United Kingdom
- Pierandrea Muglia
-
Contributed equally to this work with: Michael R. Johnson, Pierandrea Muglia, David J. Balding
Affiliation Discovery Medicine, Neurosciences CEDD, GlaxoSmithKline R&D, Verona, Italy
- David J. Balding
-
Contributed equally to this work with: Michael R. Johnson, Pierandrea Muglia, David J. Balding
Affiliations Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom, Genetics Institute, University College London, London, United Kingdom
Competing Interests
F. Tozzi, V. Mooser, D. Waterworth and N. W. Galwey are GlaxoSmithKline (GSK) full-time employees. P. Muglia was a GlaxoSmithKline full-time employee at the time when this study was performed. M. Johnson was a GSK consultant at the time when the project was initiated. F. Calboli was supported by a GSK grant to Imperial College London. The PsyCoLaus study was supported by grants from the Swiss National Science Foundation (#3200B0-105993, #3200B0-118308, 33CSCO-122661) and from GlaxoSmithKline (Psychiatry Center of Excellence for Drug Discovery and Genetics Division, Drug Discovery - Verona, R&D). GSK's role does not alter the authors' adherence to the PLoS ONE policies on sharing data.
Author Contributions
Conceived and designed the experiments: FCFC FT NWG MJ PM DB. Wrote the paper: FCFC FT NWG MJ DB. Contributed to data analysis and manuscript writing: AA. Contributed to the design of the population based study and to the writing of the manuscript: VM. Conceived the design of the population based study: MP PV GW. Principal Investigators of the study: MP PV GW. Contributed to the design of the current study and critically reviewed the manuscript: MP PV GW. Contributed to the design of the population based study and critically reviewed the manuscript: DW. Supervised the work and contributed with a critical review of the manuscript: PM DB.